Navigation Links
Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Date:5/5/2008

d are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements or transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, security holder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove t
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... More Effective Than rituximab ... in a Pre-Clinical ... announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing complement ... a pre-clinical study. The CD20,antibodies were incubated with tumor cells ...
... YORK, Sept. 6 Globally, approximately 418 million,people ... danger, and costs of hepatitis in the 21st ... Hepatitis Strategies, a,new report by Kalorama Information. ... not,taking the necessary steps to contain hepatitis. Yet ...
... Globally, approximately 418 billion,people are currently infected with ... hepatitis in the 21st century cannot be,understated or ... by Kalorama Information. Paradoxically, despite the obvious ... to contain hepatitis. Yet the incidence and,prevalence of ...
Cached Biology Technology:Genmab Announces Encouraging Preclinical Data for ofatumumab 2Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health 2Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2
(Date:4/18/2014)... For decades, scientists have used techniques like X-ray crystallography ... insight into the atomic structure of molecules, but such ... they demand large quantities of a specific molecule and ... making it all but impossible to peer into ... say those problems may soon be a thing of ...
(Date:4/18/2014)... twist to the story of how barnyard chickens came to ... the journal Proceedings of the National Academy of Sciences ... lived 200-2300 years ago in Europe, researchers report that just ... far different from the chickens we know today. , The ... modern domestic chickens -- such as their yellowish skin -- ...
(Date:4/18/2014)... A team of researchers led by a University ... to receive a $7.5 million Department of Defense grant ... basic scientific foundations for the predictable design of light-weight, ... diversity of structures from plants and animals, including the ... what biological systems have constructed over millions of years ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Ancient DNA offers clues to how barnyard chickens came to be 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
... Holick, a professor of medicine, physiology and biophysics at ... the understanding of vitamin D and its role in ... Prize for Health Research. The prize was presented ... by the Linus Pauling Institute at Oregon State University. ...
... this summer,s lineup of lectures called Distinctive Voices@The ... Hole, Massachusetts, feature diverse subjects for those curious ... the program will explore science and technology,s role ... and creativity. Award-winning scientists and engineers -- ...
... made new inroads into understanding the regulatory circuitry of ... of daily activities, according to two studies published May ... clocks and temperature, reported in Cell , offers ... the 24-hour circadian rhythm does not change with temperature ...
Cached Biology News:Vitamin D expert receives Linus Pauling Prize for Health Research 2Woods Hole lecture series explores range of scientific topics 2Two new studies on circadian rhythms 2
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
... min) assay can detect H2O2 or peroxidase ... H2O2 oxidizes ADHP in a 1:1 stoichiometry ... at 530-571 nm, emission at 590-600 nm). ... a one-step, homogeneous, no wash assay system. ...
Biology Products: